MARC GAUTIER M.D.
Prescription History 1477571297
Internal Medicine - Hematology & Oncology in Lebanon, NH

NPI Status: Active since July 18, 2006

Contact Information

1 MEDICAL CENTER DR
SECTION OF HEMATOLOGY/IONCOLOGY
LEBANON, NH
ZIP 03756
Phone: (603) 650-5529
Fax: (603) 650-5830

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MARC GAUTIER M.D., an active Hematology & Oncology specialist practicing in Lebanon, NH. Our medical registry currently tracks 21 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 722 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 100 claims alone.


Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Hematology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
NH State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills38.6
Peer Average Days Supply1,155
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.9% less volume than the regional standard for practitioners inside NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $55,471.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,267.05

State Avg Cost Per Claim

$4,881.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Acyclovir

Generic Formulation: AcyclovirSpecialty: Hematology
Provider Metrics Summary
Total Claims 77
30-Day Fills 91.0
Days Supply 2,730
NH State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills34.4
Peer Average Days Supply958
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 266.7% higher than the standard regional baseline profile for NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,313.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.06

State Avg Cost Per Claim

$24.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology
Provider Metrics Summary
Total Claims 100
30-Day Fills 202.0
Days Supply 6,038
NH State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills123.7
Peer Average Days Supply3,683
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 100.0% higher than the standard regional baseline profile for NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,626.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.27

State Avg Cost Per Claim

$26.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Hematology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 502
NH State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.4
Peer Average Days Supply664
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $261,137.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,361.05

State Avg Cost Per Claim

$14,072.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology
Provider Metrics Summary
Total Claims 16
30-Day Fills 20.7
Days Supply 412
NH State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills29.8
Peer Average Days Supply466
Conservative Utilization

This provider writes prescriptions for this formulation 38.5% less frequently than the standard regional baseline metric for practitioners inside NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $287.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.97

State Avg Cost Per Claim

$19.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Exemestane

Generic Formulation: ExemestaneSpecialty: Hematology
Provider Metrics Summary
Total Claims 24
30-Day Fills 26.0
Days Supply 780
NH State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills43.5
Peer Average Days Supply1,286
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,203.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$216.83

State Avg Cost Per Claim

$282.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Gabapentin

Generic Formulation: GabapentinSpecialty: Hematology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 420
NH State Average Benchmarks
Peer Average Claims72.0
Peer Average 30-Day Fills111.8
Peer Average Days Supply3,248
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.6% less volume than the regional standard for practitioners inside NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $178.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.72

State Avg Cost Per Claim

$24.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology
Provider Metrics Summary
Total Claims 68
30-Day Fills 155.0
Days Supply 4,555
NH State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills57.5
Peer Average Days Supply1,704
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 142.9% higher than the standard regional baseline profile for NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,510.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.92

State Avg Cost Per Claim

$38.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
NH State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.8
Peer Average Days Supply593
Conservative Utilization

This provider writes prescriptions for this formulation 31.6% less frequently than the standard regional baseline metric for practitioners inside NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,010.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$308.49

State Avg Cost Per Claim

$2,005.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematology
Provider Metrics Summary
Total Claims 73
30-Day Fills 73.0
Days Supply 2,031
NH State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.2
Peer Average Days Supply764
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 170.4% higher than the standard regional baseline profile for NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,128,278.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,455.87

State Avg Cost Per Claim

$15,456.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Jakafi

Generic Formulation: Ruxolitinib PhosphateSpecialty: Hematology
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 1,050
NH State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.7
Peer Average Days Supply741
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 45.8% more claims than the standard regional baseline profile for NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $560,346.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,009.91

State Avg Cost Per Claim

$16,179.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system).

Lenalidomide

Generic Formulation: LenalidomideSpecialty: Hematology
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 973
NH State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$15,662.27

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology
Provider Metrics Summary
Total Claims 21
30-Day Fills 56.3
Days Supply 1,690
NH State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills116.1
Peer Average Days Supply3,475
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.3% less volume than the regional standard for practitioners inside NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $885.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$42.17

State Avg Cost Per Claim

$32.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Ninlaro

Generic Formulation: Ixazomib CitrateSpecialty: Hematology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 378
NH State Average Benchmarks
Peer Average Claims11.0
Peer Average 30-Day Fills11.0
Peer Average Days Supply308
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 27.3% more claims than the standard regional baseline profile for NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $200,902.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,350.18

State Avg Cost Per Claim

$12,027.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of cancer (multiple myeloma). It works by slowing or stopping the growth of cancer cells.

Pomalyst

Generic Formulation: PomalidomideSpecialty: Hematology
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 980
NH State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.5
Peer Average Days Supply569
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 75.0% higher than the standard regional baseline profile for NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $766,648.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$21,904.24

State Avg Cost Per Claim

$21,515.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pomalidomide is used to treat certain types of cancers (such as multiple myeloma, Kaposi sarcoma). It works by slowing or stopping the growth of cancer cells.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology
Provider Metrics Summary
Total Claims 33
30-Day Fills 35.7
Days Supply 828
NH State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills48.6
Peer Average Days Supply938
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $143.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.34

State Avg Cost Per Claim

$7.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Promacta

Generic Formulation: Eltrombopag OlamineSpecialty: Hematology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
NH State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills15.0
Peer Average Days Supply450
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $245,366.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,631.45

State Avg Cost Per Claim

$12,084.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP) or who have chronic hepatitis C. It may also be used to treat people with a certain blood disorder (aplastic anemia). Platelets are a type of blood cell needed to form blood clots and prevent bleeding. Eltrombopag decreases your risk of bleeding by increasing the number of platelets. Eltrombopag acts like a certain natural substance (thrombopoietin) that causes the body to produce platelets.

Revlimid

Generic Formulation: LenalidomideSpecialty: Hematology
Provider Metrics Summary
Total Claims 70
30-Day Fills 70.0
Days Supply 1,960
NH State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.6
Peer Average Days Supply780
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 150.0% higher than the standard regional baseline profile for NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,307,510.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,678.72

State Avg Cost Per Claim

$18,233.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Scemblix

Generic Formulation: Asciminib HydrochlorideSpecialty: Hematology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NH State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$18,690.39

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Asciminib is used to treat a certain type of cancer (chronic myeloid leukemia-CML). Asciminib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Hematology
Provider Metrics Summary
Total Claims 16
30-Day Fills 30.3
Days Supply 910
NH State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills75.1
Peer Average Days Supply2,249
Conservative Utilization

This provider writes prescriptions for this formulation 44.8% less frequently than the standard regional baseline metric for practitioners inside NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $572.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.78

State Avg Cost Per Claim

$37.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Venclexta

Generic Formulation: VenetoclaxSpecialty: Hematology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 424
NH State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.4
Peer Average Days Supply560
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $145,222.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,067.92

State Avg Cost Per Claim

$10,315.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MARC GAUTIER M.D. provides transparency into local medical care patterns within Lebanon, NH.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.